Paper9060552
Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.
Brice P and 9 others. J Clin Oncol, 1997. Cited by 527 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. Papers, record 9060552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9060552
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Antineoplastic Agents, Alkylating | Major topic |
| Interferon-alpha | Major topic |
| Lymphoma, Follicular | Major topic |
| Adult | |
| Aged | |
| Disease Progression | |
| Drug Administration Schedule | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Prednimustine | |
| Prospective Studies |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03823365 | Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia | Background |
Source ClinicalTrials.gov
Cited by244
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 527 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,979,489 | Low tumor burden follicular lymphoma: The state of the art. | Hemasphere | 2026 | https://conductscience.org/library/papers/42979489 | PubMed |
| 42,903,357 | Newly diagnosed and relapsed follicular lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up. | Hemasphere | 2026 | https://conductscience.org/library/papers/42903357 | PubMed |
| 42,657,590 | LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma. | Br J Haematol | 2026 | https://conductscience.org/library/papers/42657590 | PubMed |
| 42,645,356 | Canadian Hematology Consensus Group Recommendations for the Management of Relapsed and/or Refractory Follicular Lymphoma. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42645356 | PubMed |
| 42,591,708 | Follicular Lymphoma Arising in an Ileal Neobladder Presenting as a Large Pelvic Mass. | IJU Case Rep | 2026 | https://conductscience.org/library/papers/42591708 | PubMed |
| 42,553,584 | First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma. | Hemasphere | 2026 | https://conductscience.org/library/papers/42553584 | PubMed |
| 42,527,721 | Follicular Lymphoma: Novel Therapies and Strategies for Optimal Therapeutic Sequencing. | Curr Oncol Rep | 2026 | https://conductscience.org/library/papers/42527721 | PubMed |
| 41,949,430 | Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study. | Br J Haematol | 2026 | https://conductscience.org/library/papers/41949430 | PubMed |
| 41,799,792 | Spontaneous Metabolic Regression in High-Burden Follicular Lymphoma: A Case Report. | Case Rep Hematol | 2026 | https://conductscience.org/library/papers/41799792 | PubMed |
| 41,779,695 | Comprehensive analysis of mortality risk factors in low-grade B-cell lymphoma. | PLoS One | 2026 | https://conductscience.org/library/papers/41779695 | PubMed |
| 41,710,665 | Metabolic Bulk Volume is an independent prognostic factor and facilitates identifying high risk cases for DLBCL patients treated with the R-CHOP. | Front Oncol | 2026 | https://conductscience.org/library/papers/41710665 | PubMed |
| 41,681,868 | Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2025. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41681868 | PubMed |
| 41,634,892 | Association between the incidence of infusion-related reactions by obinutuzumab and the dose of corticosteroid as premedication: a multicenter retrospective cohort study. | J Pharm Health Care Sci | 2026 | https://conductscience.org/library/papers/41634892 | PubMed |
| 41,329,901 | FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma. | J Clin Oncol | 2026 | https://conductscience.org/library/papers/41329901 | PubMed |
| 41,323,446 | Transformation of Primary Small Intestinal Follicular Lymphoma to CD20-Negative Diffuse Large B-Cell Lymphoma following Rituximab Treatment: A Case Report. | Case Rep Gastroenterol | 2025 | https://conductscience.org/library/papers/41323446 | PubMed |
| 41,283,583 | Trousseau's Syndrome and Marantic Endocarditis in a Patient with Pulmonary Adenocarcinoma: A Case Report and a Brief Review of the Literature. | Reports (MDPI) | 2025 | https://conductscience.org/library/papers/41283583 | PubMed |
| 41,114,104 | Colorectal follicular lymphoma: A single-center retrospective study. | World J Gastrointest Oncol | 2025 | https://conductscience.org/library/papers/41114104 | PubMed |
| 41,058,067 | Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective. | Hematol Oncol | 2025 | https://conductscience.org/library/papers/41058067 | PubMed |
| 40,994,345 | Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study. | Haematologica | 2026 | https://conductscience.org/library/papers/40994345 | PubMed |
| 40,966,421 | Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma. | Blood Adv | 2025 | https://conductscience.org/library/papers/40966421 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9060552
GET https://conductscience.org/api/papers/v1/9060552/cited_by?page=2